10 Results for "

KYSE520

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "KYSE520" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-161952
CAS No.: 2245082-05-5
Synonyms: JAB-3312
Target:  

SHP2

Research Areas:  

Cancer

Sitneprotafib (JAB-3312) is an orally effective anticancer phosphatase SHP2 inhibitor (IC50: 1.9 nM) with anti-cancer activity. Sitneprotafib has good tolerability and significantly induced tumor regression in a KYSE-520 mouse xenograft model .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145162
CAS No.: 2458219-65-1
Purity:  95.83%
Research Areas:  

Cancer

SHP2-D26 is a SHP2 PROTAC degrader with DC50 values of 6.0 nM (KYSE520 cells) and 2.6 nM (MV4;11 cells), respectively. SHP2-D26 inhibits ERK phosphorylation, upregulates Bim levels, downregulates Mcl-1 levels, and induces cell cycle arrest and apoptosis. SHP2-D26 can be used in studies related to esophageal cancer, acute myeloid leukemia and non-small cell lung cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-114397
CAS No.: 2055757-40-7
Purity:  99.66%
Target:  

SHP2 Phosphatase

Research Areas:  

Cancer

SHP394 is an orally active, selective and allosteric inhibitor of SHP2, with an IC50 of 23 nM .
loading...
    loading...
Cat. No.: HY-145703
CAS No.: 2740582-16-3
Purity:  99.76%
Target:  

PROTACs Drug Isomer

Research Areas:  

Others

SHP2-D26 isomer-1 (Compound 26) is an isomer of SHP2-D26 (HY-145162). SHP2-D26 is the first highly potent SHP2 PROTAC degrader. The induction of SHP2 degradation by SHP2-D26 requires binding to VHL-1 and SHP2 proteins, and is dependent on ubiquitin-like modification and the proteasome. SHP2-D26 can be used in the research of esophageal cancer and acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-172911
CAS No.: 3086289-71-3
Target:  

SHP2

Research Areas:  

Cancer

SHP2-IN-37 (compound C5) is a potent and selective SHP2 allosteric inhibitor with an IC50 of 0.023 μM. SHP2-IN-37 exhibits antiproliferative effect on KYSE-520 and MV-411 cells with IC50s of 6.97 and 0.67 μM, respectively
loading...
    loading...
Cat. No.: HY-174239
CAS No.: 3081261-84-6
Target:  

SHP2

Research Areas:  

Cancer

SHP2-IN-41 (Compound 4) is a SHP2 inhibitor with an IC50 of less than 0.1 μM. SHP2-IN-41 has an IC50 against KYSE-520 cells also less than 0.1 μM. SHP2-IN-41 can be used in the study of cancer .
loading...
    loading...
Cat. No.: HY-172454
Target:  

SHP2

Research Areas:  

Cancer

SHP2-IN-36 (Compound B8) is an allosteric inhibitor of SHP2, with an IC50 value of 9.0 nM. In addition, its IC50 for p-ERK is 40 nM. SHP2-IN-36 also exhibited significant antitumor activity in the KYSE520 xenograft mouse model. SHP2-IN-36 can be used for research in the field of anti-tumor .
loading...
    loading...
Cat. No.: HY-178962
Target:  

Drug Metabolite

Research Areas:  

Cancer

Antitumor agent-207 (compound 10K) is a Pt(IV)-NO prodrug with high lipid solubility, good stability, and excellent tumor targeted release ability. Antitumor agent-207 has significant anti proliferative activity in various cells such as TE-1 (IC50 = 1.79 μM), TE-10 (IC50 = 1.95 μM), KYSE-30 IC50 = 5.99 μM), KYSE-520 (IC50 = 5.53 μM) cells. Antitumor agent-207 can significantly enhance intracellular Pt accumulation and DNA platformization levels, and effectively release NO. Antitumor agent-207 can be used for research on cancers such as esophageal cancer .
loading...
    loading...
Cat. No.: HY-P991969

Target:  

EGFR

Research Areas:  

Cancer

LR004 is an EGFR monoclonal antibody, with a Kd of 2.80×10 -9 M against human EGFR. LR004 shows extremely weak inhibitory effect on the viability of EGFR-positive tumor cells in vitro, but inhibits the growth of EGFR-positive tumor xenografts as a single agent. LR004 is applicable to research related to advanced colorectal cancer, solid tumors, esophageal squamous cell carcinoma, epidermoid carcinoma, colon cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-184650
Target:  

SHP2 NAMPT Apoptosis ERK

Research Areas:  

Cancer

SHP2/NAMPT-IN-1 is an orally active dual inhibitor of SHP2 and NAMPT, with IC50 values of 30.5 nM and 24.4 nM, respectively. SHP2/NAMPT-IN-1 reduces NAD+ levels and p-ERK expression by inhibiting NAMPT. SHP2/NAMPT-IN-1 can inhibit the migration and colony formation of MDA-MB-231 cells and promote apoptosis. SHP2/NAMPT-IN-1 has anti-proliferative activity against a variety of tumor cell lines and can reverse PD-L1-mediated T-cell immunosuppression. SHP2/NAMPT-IN-1 can be used for breast cancer research .
loading...
    loading...